Gilead Sciences announced pricing plans for its coronavirus-fighting drug remdesivir. It will charge the US government and other developed countries $390 per vial, or about $2,340 for a typical five-day course of treatment.
The US biopharmaceutical company said it would offer a one-price model to avoid the need for country-by-country negotiations that could slow down access. For commercially insured patients, the five-day course will cost $3,120. The longer 10-day treatment course will cost governments $4,290 per patient and $5,720 for a US patient with private insurance.
Continue reading https://on.rt.com/akl4